Schrödinger, Inc. Website

Schrödinger, Inc.

NasdaqGS-SDGR

Company Overview

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

  • Name

    Schrödinger, Inc.

  • CEO

    Ramy Farid

  • Website

    www.schrodinger.com

  • Sector

    Health Care Technology

  • Year Founded

    1990

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 13, 2025 - Dec 13, 2025

Schrodinger Inc. Navigates Mixed Market Sentiment with Key Developments

  • A significant bullish event occurred when management announced a meeting with KeyBanc, generating positive investor interest.
  • Regulatory guidance from the FDA is expected to benefit Schrodinger's positioning in biopharmaceutical research.
  • Analyst downgrades introduced bearish sentiment, impacting share value despite moments of optimism.

Over the past month, Schrodinger Inc. (SDGR) experienced a modest overall increase of 0.5%. This performance outpaced the S&P 500's decline of 0.2% by a margin of 0.7%. However, SDGR underperformed relative to the Health Care sector (XLV), which saw a decrease of 0.3%, indicating mixed sentiment surrounding the company during this period.

A notable bullish event took place on November 24 when Schrodinger management announced an upcoming meeting with KeyBanc in New York scheduled for December 1. This announcement generated positive investor interest as it was anticipated to provide insights into the company's strategic direction and operational updates, engaging analysts and investors alike. Following this news, SDGR experienced a price increase of approximately 4.4%, reflecting market optimism regarding future developments.

On December 2, further bullish momentum emerged due to guidance from the FDA aimed at streamlining nonclinical safety studies for monoclonal antibodies, particularly monospecific antibodies. Analysts at Craig Hallum identified Schrodinger as one among several companies poised to benefit from these regulatory changes because of its simulation and modeling platforms designed for pharmaceutical firms navigating new requirements; consequently, the stock responded positively with an uptick of around 1.5%.

Conversely, bearish sentiment arose on November 17 when Morgan Stanley analyst Sean Laaman downgraded SDGR’s price target from $19 to $18 while maintaining an Equalweight rating on the stock; this revision reflected lowered expectations for SDGR's performance and negatively impacted investor sentiment during that time as evidenced by a slight decline in share value by about 1.4%. Overall, while there were instances driven by strategic meetings and favorable regulatory developments that fostered optimism within investors' minds throughout the month—these were somewhat tempered by negative analyst revisions affecting market perception.

Schrodinger Inc underperformed the Health Care (XLV) sector by -0.3%.

NasdaqGS:SDGR